 Shares of UniQure gained 7.2 in trading on Monday after the company said an independent data safety monitoring board said there were no safety concerns in a Phase 23 clinical trial for its experimental Huntingtons disease treatment. The board has reviewed six months of safety data for the first two patients enrolled in the randomized, double-blind study. 